BMS to Construct a New Large-Scale Biologics Manufacturing Facility in Cruiserath, Ireland
Bristol-Myers Squibb (BMS) has announced plans to construct a new, large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland, that will produce multiple therapies for the company’s growing biologics portfolio. Once completed, the new facility will significantly increase BMS’s biologics manufacturing capacity and play a central role in its global manufacturing network.
BMS has a robust and growing portfolio of approved and investigational biologic medicines across multiple therapeutic areas including oncology, virology and immunoscience. Biologic medicines are an increasingly important tool in the treatment of serious diseases and comprise more than half of BMS’s R&D pipeline.
“Our investment in this new facility reflects the strength of our business and the increasingly important role that biologic medicines will play in BMS’s future,” said Lamberto Andreotti, chief executive officer, BMS. “For 50 years, BMS has maintained a significant manufacturing presence in Ireland, and we look forward to building on that legacy through this significant expansion of our manufacturing capability.”
“I greatly welcome this investment by BMS, which is a huge boost to the Irish economy,” said Mr Enda Kenny TD, Prime Minister of Ireland. “I had the opportunity to meet with BMS, and I'm delighted they chose Ireland as the location for this large, state-of-the-art facility. Not only will 1000 construction jobs be created in the initial phase, but the facility will support up to 400 jobs for skilled professionals. The government has a plan to secure recovery so that Ireland can attract new jobs and investments such as those being announced today.”
The 30,000-square meter project will house six 15,000-L bioreactors and a purification area, as well as office and laboratory space. The plant will be built on the grounds of the company’s existing bulk pharmaceutical manufacturing plant.
BMS’s Board of Directors has approved initial funding that will support the first phase of the project. The full cost of the facility, expected to be finalized in the second half of 2015, is anticipated to be comparable to the approximately $900 million investment to construct and operationalise the company’s biologics manufacturing facility in Devens, Massachusetts.
Approximately 350–400 scientists, engineers, bioprocess operators, quality specialists and other skilled professionals are expected to work at the facility when construction is completed, and the construction programme is expected to create about 1000 jobs. The completion of the facility, including commissioning and validation, is anticipated to take approximately 4 years and is estimated to be operational in 2019.
Related News
-
News Abortion pills can now be sold in retail pharmacies according to the US FDA
In the US, retail pharmacies will be allowed to sell abortion pills for the first time, after latest approval is granted by the FDA. -
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News CPHI Frankfurt: Interview with Marcelo Cruz, Vice President, Business Development & Marketing at Tjoapack
In this series of interviews, we caught up with some of the exhibitors at CPHI Frankfurt to discover what innovations are being brought to the pharmaceutical industry this year. Here we chat with Marcelo Cruz of Tjoapack to discuss how global events ar... -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News Trend Report: The True Cost of API Price Rises
Download our Trend Report to discover what the current landscape of APIs and their pricing means for the pharmaceutical industry in the future. -
News Alzheimer's drug lecanemab shows reduced cognitive decline in clinical trial
A monoclonal antibody drug, named lecanemab, has been tested in a Phase III clinical trial in nearly 1800 participants, with promising results in reducing the effects of Alzheimer's disease on the brain.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance